ClinicalTrials.gg
CompletedNCT04472065PACEUpdated Oct 25, 2023

Study of Probiotic Use After Childbirth in Relation to Emotional Well-Being

An interventional study of Lactobacillus reuteri and Placebo in Mental Health Wellness, sponsored by Elizabeth Austen Lawson. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-25.

Sponsored by Elizabeth Austen Lawson · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Researchers at Massachusetts General Hospital are interested in learning more about the neurobiology of well-being in new mothers and novel ways to support them during their transition to parenthood. This study aims to evaluate well-being in new mothers and their infant and the impact of a probiotic dietary supplement on the gut microbiome. This study hopes to help improve the existing knowledge of maternal postnatal health.

02

Conditions studied

  • Mental Health Wellness

Keywords

  • Gut microbiome
  • Postpartum depression
  • Oxytocin
  • Socio-emotional functioning
  • Probiotic
03

In context

Depression, Postpartum

569 studies on the registry are indexed under Depression, Postpartum; 134 are open to participants now.

This study's enrollment of 46 is below the median of 104 across 454 interventional studies indexed under Depression, Postpartum.

Browse Depression, Postpartum studies →

Lead sponsor

Elizabeth Austen Lawson is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to give written
  2. Expectant mothers with singleton infant or mothers who have recently given birth to a singleton infant
  3. At least 18 years of age
  4. At risk for postpartum depression as defined: a hx of depression and/or, a hx of postpartum depression and/or by a prenatal EPDS score ≥ 8

Exclusion criteria

Exclusion Criteria:

  1. Has active substance abuse in the past 6 months or a history of opioid use disorder
  2. Has diabetes mellitus except for diet controlled gestational diabetes
  3. Has uncontrolled thyroid disease
  4. Has inflammatory gastrointestinal disease
  5. Has active suicidal ideation
  6. Has a history of psychosis
  7. Has a history of an autism spectrum disorder
  8. Plans to take other probiotics (other than study product) during study participation
  9. Plans to take systemic hormonal during study participation (Note: intra-uterine device is allowed)
  10. Is receiving any systemically administered medication on a chronic basis
  11. Has a or uncontrolled concomitant illness or condition that would put the subject at risk or jeopardize the objectives of the study
  12. Has a , sensitivity, or known allergy to any ingredient of the study product
  13. Is considered, in the opinion of the Principal Investigator (PI), to likely be a poor attendee or unlikely for any reason to be able to comply with the study procedures
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
46 participants (actual)

Study arms

  • Active comparator
    Subjects receiving Probiotic Dietary Supplement

    Dietary Supplement: Lactobacillus reuteri

  • Placebo comparator
    Subjects receiving Placebo

    Other: Placebo

Interventions

  • Dietary supplementLactobacillus reuteri

    1 chewable tablet of probiotic dietary supplement (200 million CFU of L. reuteri DSM 17938 and ATCC PTA 6475) consumed once per day orally for 6 weeks beginning at Baseline (between 1 to 3 days postpartum) to 6 weeks postpartum.

  • OtherPlacebo

    1 chewable placebo tablet containing all the same ingredients except L. reuteri (DSM 17938 and ATCC PTA 6475) consumed once per day orally for 6 weeks beginning at Baseline (between 1 to 3 days postpartum) to 6 weeks postpartum.

06

What researchers measure

Primary outcomes

  1. Coding Interactive Behavior (CIB) Negative Scale Score (range: 1-5; direction: Higher values indicate worse maternal responses) in the probiotic versus placebo group

    Mother-infant bonding: Quantitative observational assessment of mother-infant bonding using the Child Interactive Behavior (CIB).

    Time frame: 6 week

Secondary outcomes

  1. Change in Toronto Alexithymia Scale (TAS-20) Total Score (range: 20-100; direction: lower scores indicate better socioemotional functioning) in the probiotic versus placebo group

    Time frame: Baseline to Week 6

  2. Change in relative abundance of microbial taxa (operational taxonomic units) in fecal samples in the probiotic versus placebo group

    Time frame: Baseline to Week 6

07

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Oct 2023, 31 months.

Of 256 non-industry interventional studies with no phase under Depression, Postpartum, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 36. This study's 31 months is above that.

Counting every sponsor, half of 262 studies reached it within 23 months; a quarter within 11 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2020
First posted
Jul 15, 2020
StartActual
Mar 10, 2021
Primary completionActual
Oct 16, 2023
CompletionActual
Oct 16, 2023
Last update
Oct 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04472065
Lead sponsor
Elizabeth Austen Lawson
Responsible party
Elizabeth Austen Lawson (Elizabeth A. Lawson, M.D., M.M.Sc., Massachusetts General Hospital) — Sponsor-investigator
First posted
Jul 15, 2020
Start date
Mar 10, 2021
Primary completion
Oct 16, 2023
Completion
Oct 16, 2023
Last update
Oct 25, 2023

Study contacts

Elizabeth A Lawson, MD, MMSc
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lactobacillus reuteri

Start the discussion